Literature DB >> 7356516

Distinction between preneopastic and neoplastic mammary cell populations in vitro by cytochalasin B-induced multinucleation.

D Medina, C J Oborn, B B Asch.   

Abstract

Epithelial cell cultures of normal mammary gland, preneoplastic hyperplastic nodule outgrowth lines, primary tumors, and transplanted tumors, all derived from BALB/c mice, were examined for their response to cytochalasin B to determine if cells of primary mammary tumors multinucleated and if preneoplastic hyperplastic alveolar nodule cells responded differently than cells of primary tumors. Established tumorigenic and nontumorigenic cell lines were also examined as positive and negative controls. The standard assay conditions were optimized at 1 microgram CB per ml for 48 hr. The results, expressed as the mean percentage of cells exhibiting three or more nuclei per cell were: normal mammary cells, 5%; preneoplastic mammary cells, 4%; primary mammary tumor cells, 36%; transplanted mammary tumors, 70%; tumorigenic established cell lines, 80%; and nontumorigenic established cell lines, 5%. The frequency of tumor cells exhibiting multinucleation increased with serial transplantation in vivo and with serial passage in vitro. The results demonstrate that neoplastic cells within a primary tumor exhibit uncontrolled nuclear division and that uncontrolled nuclear division is a distinguishing characteristic between preneoplastic and neoplastic mammary cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7356516

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Chemical carcinogen-mouse mammary tumor virus interactions in cell transformation.

Authors:  D K Howard; J Schlom; P B Fisher
Journal:  In Vitro       Date:  1983-01

2.  Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration.

Authors:  Matthew Trendowski; Joan M Mitchell; Christine M Corsette; Christopher Acquafondata; Thomas P Fondy
Journal:  Invest New Drugs       Date:  2015-01-06       Impact factor: 3.850

3.  Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models.

Authors:  Matthew Trendowski; Joan M Mitchell; Christine M Corsette; Christopher Acquafondata; Thomas P Fondy
Journal:  Invest New Drugs       Date:  2015-01-07       Impact factor: 3.850

4.  Using cytochalasins to improve current chemotherapeutic approaches.

Authors:  Matthew Trendowski
Journal:  Anticancer Agents Med Chem       Date:  2015       Impact factor: 2.505

5.  Preparation, In Vivo Administration, Dose-Limiting Toxicities, and Antineoplastic Activity of Cytochalasin B.

Authors:  Matthew Trendowski; Joseph N Zoino; Timothy D Christen; Christopher Acquafondata; Thomas P Fondy
Journal:  Transl Oncol       Date:  2015-08       Impact factor: 4.243

6.  Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro.

Authors:  Matthew Trendowski; Timothy D Christen; Christopher Acquafondata; Thomas P Fondy
Journal:  BMC Cancer       Date:  2015-09-10       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.